Publikationen

Zeuschner P, Meyer I, Siemer S, Stoeckle M., Wagenpfeil G, Wagenpfeil S, Saar M, Janssen M. (2021) Three different learning curves have an independent impact on perioperative outcomes after robotic partial nephrectomy – a comparative analysis. Ann Surg Oncol. 28(2):1254-1261

Zeuschner P, Greguletz L, Meyer I, Linxweiler J, Janssen M, Wagenpfeil G, Wagenpfeil S, Siemer S, Stöckle M, Saar M (2021). Open versus robot-assisted partial nephrectomy: a longitudinal comparison of 880 patients over 10 years. Int J Med Robot. 17(1):1-8

Abdeen M, Janssen M, Al-Kailani Z, Saar M, Siemer S, Stöckle M, Aßmann G, Linxweiler J (2021). When a urological emergency indicates an internal medical crisis: Priapism as the first clinical manifestation of leukemia. Urologe A. 60(1):67-70

Niklas C, Saar M, Nini A, Linxweiler J, Siemer S, Junker K, Stoeckle M (2021). Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance? World J Urol. 39(9):3231-3237

Linxweiler J, Sprenk J, Cascetta K, Pryalukhin A, Hölters S, Zeuschner P, Nini A, Al-Kailani Z, Ezziddin S, Bohle RM, Fries P, Ohlmann CH, Heinzelbecker J, Siemer S, Stöckle M, Junker K*, Saar M* (2021). Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management. J Urol. 206(1):88-96

Ayoubian H, Heinzelmann J, Hölters S, Khalmurzaev O, Pryalukhin A, Loertzer P, Heinzelbecker J, Lohse S, Geppert C, Loertzer H, Wunderlich H, Bohle RM, Stöckle M, Matveev VB, Hartmann A, Junker K (2021). miRNA Expression Characterizes Histological Subtypes and Metastasis in Penile Squamous Cell Carcinoma. Cancers. 13(6):1480

Zeuschner P, Linxweiler J, Mohr R, van Heemskerk S, Wagenpfeil G, Wagenpfeil S, Ohlmann C, Siemer S, Stöckle M, Saar M (2021). Robot-assisted versus open radical cystectomy: A cohort study on perioperative outcomes accounting for stage selection bias and surgical experience. Int J Med Robot. 17(4):e2258

Zeuschner P, Vollmer SG, Linxweiler J, Wagenpfeil G, Wagenpfeil S, Saar M, Siemer S, Stöckle M, Heinzelbecker J (2021). Robot-assisted versus open radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: A retrospective cohort study across ten years. Surg Oncol. 38:101607

Ohlmann CH, Saar M, Pierchalla LC, Zangana M, Bonaventura A, Stöckle M, Siemer S, Heinzelbecker J (2021). Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours. Sci Rep. 11(1):10700

Zeuschner P, Hölters S, Stöckle M., Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm M-O, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Staehler M, Junker K (2021). Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers. 13(11): 2594.

Zeuschner P, Siemer S (2021). Robot-assisted surgery for renal cell carcinoma - today a standard? Aktuelle Urol. 52(5):464-473

Zeuschner P, Zaccagnino A, Junker K (2021). Biomarkers for renal cell tumours. Aktuelle Urol. 52(5):452-463

Heinzelbecker J, Ruf C (2021). non-metastasised clincial stage I testicular germ cell tumours: Patient information, suitability and limitations of surveillance. Urologe A. 60(7):854-861

Zeuschner P, Stöckle M, Peters R, Miller K, Liefeldt L, Halleck F, Budde K, Hennig L, Friedersdorff F (2021). Does the Side Matter? A Retrospective Cohort Study Comparing Left and Right Pure Laparoscopic Donor Nephrectomies. Urol Int. 105(11-12):1076-1084

Linxweiler J, Kolbinger A, Himbert D, Zeuschner P, Saar M, Stöckle M, Junker K (2021). Organ-Specific Uptake of Extracellular Vesicles Secreted by Urological Cancer Cells. Cancers.13(19):4937

Nini A, Muttin F, Cianflone F, Carenzi C, Lucianó R, Catena M, Larcher A, Salvioni M, Cazzaniga W, Pederzoli F, Matloob R, Colombo R, Paganelli M, Salonia A, Briganti A, Doglioni C, Zangrillo A, De Cobelli F, Rigatti P, Freschi M, Cornero G, Nicoletti R, Aldrighetti L, Montorsi F, Capitanio U, Bertini R (2021). Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. Minerva Urol Nefrol. 73(6):746-753

Prudhomme T, Beauval JB, Lesourd M, Roumiguié M, Decaestecker K, Vignolini G, Campi R, Serni S, Territo A, Gausa L, Tugcu V, Sahin S, Alcaraz A, Musquera M, Stockle M, Janssen M, Fornara P, Mohammed N, Del Bello A, Kamar N, Sallusto F, Breda A, Doumerc N (2021). Robotic-assisted kidney transplantation in obese recipients compared to non-obese recipients: the European experience. World J Urol. 39(4):1287-1298

Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M (2021). Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World J Urol. 39(1):65-72

Musquera M, Peri L, Ajami T, Breda A, Campi R, Tugcu V, Decaestecker K, Stockle M, Fornara P, Doumerc N, Vigues F, Barod R, Desender L, Territo A, Serni S, GrazianoVignolini, Sahin S, Zeuschner P, Banga N, Alcaraz A (2021). Robotic Assisted Kidney Transplantation: Update from the ERUS series. BJU Int. 127(2):222-228

Erlmeier F, Steffens S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Ivanyi P; (German Network Of Kidney Cancer) (2021). Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Clin Genitourin Cancer. 19(1):53-59

Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M (2021). Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). J Cancer Res Clin Oncol. 147(1):235-242

Staehler M, Stöckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Brüning F, Goebell PJ, Augustin M, Roos F, Benz-Rüd I, Marschner N, Grünwald V (2021). Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Int J Cancer. 148(7):1685-1694

Bernhard MC, Zwick A, Mohr T, Gasparoni G, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Naumann CM, Kalthoff H, Junker K, Smola S, Lohse S (2021). The HPV and p63 status in penile cancer are linked with the infiltration and therapeutic availability of neutrophils. Mol Cancer Ther. 20(2):423-437

Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021). Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urol Int. 105(3-4):169-180

Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021). Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. Urol Int. 105(3-4):181-191

Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C (2021). The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World J Urol. 39(9):3407-3414

Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F (2021). Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics. 11(9):4050-4060

Casper M, Linxweiler M, Linxweiler J, Zimmermann R, Glanemann M, Lammert F, Weber SN (2021). SEC62 and SEC63 Expression in Hepatocellular Carcinoma and Tumor-Surrounding Liver Tissue. Visc Med. 37(2):110-115.

Erdbrügger U, Blijdorp CJ, Bijnsdorp IV, Borràs FE, Burger D, Bussolati B, Byrd JB, Clayton A, Dear JW, Falcón-Pérez JM, Grange C, Hill AF, Holthöfer H, Hoorn EJ, Jenster G, Jimenez CR, Junker K, Klein J, Knepper MA, Koritzinsky EH, Luther JM, Lenassi M, Leivo J, Mertens I, Musante L, Oeyen E, Puhka M, van Royen ME, Sánchez C, Soekmadji C, Thongboonkerd V, van Steijn V, Verhaegh G, Webber JP, Witwer K, Yuen PST, Zheng L, Llorente A, Martens-Uzunova ES (2021). Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. J Extracell Vesicles. 10(7):e12093

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators (Stoeckle M, Ohlmann C) (2021).  Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22(7):931-945

Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S (2021). Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 48(1):103-112

Rosar F, Krause J, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Ezziddin S, Khreish F (2021). Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceutics. 13(5):722

Iqbal U, Elsayed AS, Jing Z, Stoeckle M, Wijburg C, Wiklund P, Hosseini A, Dasgupta P, Khan MS, Hemal A, Kim EH, Wagner AA, Gaboardi F, Rha KH, Maatman T, Balbay D, Li Q, Hussein A, Guru KA Dr (2021). Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Endourol. 35(10):1541-1547

Rosar F, Kochems N, Bartholomä M, Maus S, Stemler T, Linxweiler J, Khreish F, Ezziddin S (2021). Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers (Basel). 13(12):3095

Nelskamp A, Schnurr B, Germanyuk A, Sterz J, Lorenz J, Sader R, Rüsseler M, Seifert LB (2021). Comparison of 'Mental training' and physical practice in the mediation of a structured facial examination: a quasi randomized, blinded and controlled study. BMC Med Educ. 23;21(1):178

Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmitz W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A (2021). MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 12(1):5066

Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S (2021). Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. Biomolecules. 11(8):1099    4,879/0,232
Khreish F, Ribbat K, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Schreckenberger M, Ezziddin S, Rosar F (2021). Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT. Cancers (Basel). 13(16):4134

Schulz GB, Stief CG, Saar M, Vögeli TA, Todenhöfer T, Knüchel R, Gaisa NT (2021). Molecular diagnostics of bladder cancer-practical ramifications. Urologe A. 60(10):1349-1358

Bley IA, Zwick A, Hans MC, Thieser K, Wagner V, Ludwig N, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Naumann CM, Kalthoff H, Junker K, Smola S, Lohse S (2021). IDKK1 inhibits canonical Wnt signaling in human papillomavirus-positive penile cancer cells. Transl Oncol. 15(1):101267

Kornienko K, Siegel F, Borkowetz A, Hoffmann MA, Drerup M, Lieb V, Bruendl J, Höfner T, Cash H, von Hardenberg J, Westhoff N; GESRU Academics Prostate Cancer Group (2021). Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study. Prostate Cancer Prostatic Dis.

Klümper N*, Schmucker P*, Hahn O, Höh B, Mattigk A, Banek S, Ellinger J, Heinzelbecker J, Sikic D, Eckstein M, Strauß A, Zengerling F, Hölzel M, Zeuschner P, Kalogirou C (2021). C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma. Clin Transl Immunology.10(12):e1358

Himbert D, Zeuschner P, Ayoubian H, Heinzelmann J, Stöckle M, Junker K (2020).  Characterization of CD147, CA9, and CD70 as tumor-specific markers on extracellular vesicles in clear cell renal cell carcinoma. Diagnostics 10(12): 1034

Stöckle M(2020). Neoadjuvant chemohormonal therapy prior to prostatectomy in high-risk prostate cancer-is biochemical recurrence an adequate surrogate marker for clinical benefit? Urologe A

Zeuschner P, Linxweiler J, Junker K (2020). Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn. 20(2): 151-167

Zeuschner P, Saar M, Janssen M (2020). ASO Author Reflection: Learning Curves in Robotic Partial Nephrectomy-Not Only the Surgeon Counts. Ann Surg Oncol

Zeuschner P, Sester U, Stöckle M, Saar M, Zompolas I, El-Bandar N, Liefeldt L, Budde K, Öllinger R, Ritschl P, Schlomm T, Mihm J, Friedersdorff F (2020). Should We Perform Old-for-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay. J Clin Med. 9(6)

Linxweiler J, Hajili T, Körbel C, Berchem C, Zeuschner P, Müller A, Stöckle M, Menger M,  Junker K*, Saar M* (2020). Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep

Zeuschner P, Siemer S, Stöckle M, Saar M. (2020) Die ersten 50 roboter-assistierten Donornephrektomien. Urologe A     

Saar M, Linxweiler J, Borkowetz A, Fussek S, Urbanova K, Bellut L, Kristiansen G, Wullich B; German Prostate Cancer Consortium (DPKK) (2020). Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey. Urol Int.

Ernst S, Heinzelmann J, Bohle RM, Weber G, Stöckle M, Junker K*, Heinzelbecker J* (2020). The metastatic potential of seminomatous germ cell tumours is associated with a specific microRNA pattern. Andrology

Junker K, Eckstein M, Fiorentino M, Montironi R (2020). PD1/PD-L1 axis in uro-oncology. Curr Drug Targets.

Zeuschner P, Hennig L, Peters R, Saar M, Linxweiler J, Siemer S, Magheli A, Kramer J, Liefeldt L, Budde K, Schlomm T, Stöckle M, Friedersdorff F (2020). Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases. J Clin Med. 26;9(6)

Zeuschner P, Siemer S (2020). New aspects in the treatment of localized renal cell carcinoma. Urologe A.

Linxweiler J, Junker K (2020). Extracellular vesicles in urological malignancies: an update. Nat Rev Urol.

Zeuschner P, Siemer S, Stöckle M (2020). Robot-assisted kidney transplantation. Urologe A

Kriegsmann M, Casadonte R, Maurer N, Stoehr C, Erlmeier F, Moch H, Junker K, Zgorzelski C, Weichert W, Schwamborn K, Deininger SO, Gaida M, Mechtersheimer G, Stenzinger A, Schirmacher P, Hartmann A, Kriegsmann J, Kriegsmann K (2020). Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. J Cancer

Hiester A, Nini A, Arsov C, Buddensieck C, Albers P (2020). Robotic-Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. J Urol.

Montorsi F, Bandini M, Briganti A, Dasgupta P, Gallina A, Gallucci M, Gill IS, Guru KA, Hemal A, Menon M, Moschini M, Murphy DG, Parekh DJ, Patel HD, Patel HRH, Stöckle M, Tewari AK, Wijburg CJ, Wiklund P, Wilson TG, Mottrie A; EAU Robotic Urology Section Scientific Working Group (2020). Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. Eur Urol.

Massmann A, Fries P, Shayesteh-Kheslat R, Buecker A, Stöckle M, Niklas C (2020). Life-threatening arterioureteral fistula treatment by endovascular complete anatomic iliac artery bifurcation reconstruction.  J Vasc Surg Cases Innov Tech. 6(2):199-204

Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A (2020). Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol.               

Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A (2020). Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. Eur Urol.

Hoffmann M.J., Taubert H., Junker K. (2020) Molekulare Grundlagen der Karzinogenese und molekularbiologische Untersuchungsmethoden. In: Rübben H., Hakenberg O., Grimm MO., Burger M. (eds) Uroonkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg

Fornara P, Stöckle M (2020). Kidney transplantation and organ donation. Urologe A. 59(1):2

Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C, Ezziddin S (2020). New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 47(3):687-694

Outeiro-Pinho G, Barros-Silva D, Aznar E, Sousa AI, Vieira-Coimbra M, Oliveira J, Gonçalves CS, Costa BM, Junker K, Henrique R, Jerónimo C (2020). MicroRNA-30a-5p me: A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma in Tissue and Urine Samples. J Exp Clin Cancer Res. 39(1):98.

Rosar F, Ribbat K, Ries M, Linxweiler J, Bartholomä M, Maus S, Schreckenberger M, Ezziddin S, Khreish F (2020). Neuron-specific Enolase Has Potential Value as a Biomarker for [ ¹⁸ F]FDG/[ ⁶⁸ Ga]Ga-PSMA-11 PET Mismatch Findings in Advanced mCRPC Patients. EJNMMI Res.10(1):52

Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S (2020). Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177 Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging

Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann KP, Brito M, Ruf C, Oing C, Bokemeyer C. (2020). Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). Eur J Cancer. 132:127-135

Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, Peabody JO, Wijburg CJ, Wagner A, Canda AE, Khan MS, Scherr D, Schanne F, Maatman TJ, Kim E, Mottrie A, Aboumohamed A, Gaboardi F, Pini G, Kaouk J, Yuh B, Rha KH, Hemal A, Palou Redorta J, Badani K, Saar M, Stockle M, Richstone L, Roupret M, Balbay D, Dasgupta P, Menon M, Guru KA (2020). A Comparative Propensity-Score Matched Analysis of Perioperative Outcomes of Intracorporeal versus Extracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. BJU Int.

Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M (2020). Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World J Urol.

Aldhaam NA, Elsayed AS, Jing Z, Richstone L, Wagner AA, Rha KH, Yuh B, Palou J, Khan MS, Menon M, Roupret M, Balbay D, Hosseini A, Wiklund P, Gaboardi F, Maatman TJ, Mottrie A, Wijburg C, Stöckle M, Hemal A, Kim E, Kaouk J, Hussein AA, Guru KA (2020). Neoadjuvant Chemotherapy Is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Utilization from the IRCC. J Urol. 203(1):57-61

Pein U, Girndt M, Markau S, Fritz A, Breda A, Stöckle M, Mohammed N, Kawan F, Schumann A, Fornara P, Weigand K (2019). Minimally invasive robotic versus conventional open living donor kidney transplantation. World J Urol

Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholomä M, Ezziddin S (2019). 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging.

Hajili T, Ohlmann CH, Linxweiler J, Niklas C, Janssen M, Siemer S, Stoeckle M, Saar M. (2019). Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up. BJU Int. 123:58–64

Zeuschner P, Ueberdiek S, Pryalukhin A, Veith C, Saar M, Smola S, Bohle RM, Junker K, Stöckle M, Heinzelbecker J (2019). Human Papillomavirus-Associated Invasive Condylomas in a Man with Immunosuppressive Comorbidities.  Urol Int. 102(2):238-242

Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Füssel S, Novotny V, Toma M, Gajda M, Lehmann J, Wunderlich H, Grimm MO, Stöckle M, Junker K (2019). A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. J Cancer Res Clin Oncol. 145(4):811-820

Linxweiler J, Hammer M, Muhs S, Kohn M, Pryalukhin A, Veith C, Bohle RM, Stöckle M, Junker K, Saar M (2019). Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer. J Cancer Res Clin Oncol. 145(3), 551-559

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M (2019). Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol. 75(4):604-611

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A (2019). High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Hum Pathol. 83:212-223

Grimm J*, Zeuschner P*, Janssen M, Wagenpfeil S, Hartmann A, Stöhr C, Keck B, Kahlmeyer A, Stöckle M, Junker K (2019). Metastatic risk stratification of clear cell renal cell carcinoma patients based on genomic aberrations. Genes Chrom Cancer 58(9):612-618

Hölters S*, Khalmurzaev O*, Pryalukhin A*, Loertzer P, Janssen M, Heinzelbecker J,  Ueberdiek S, Pfuhl T, Smola S, Agaimy A, Geppert C, Loertzer H, Krah X,  Wunderlich H, Wagenpfeil S, Bohle R, Stöckle M, Matveev V, Hartmann*, A, Junker K* (2019). Challenging the prognostic impact of the new WHO and TNM classifications with special emphasis on HPV status in penile carcinoma. Virchows Archiv    475(2):211-221

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G (2019). Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 37(16):1412-1423

Stöckle M (2019). Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. Eur Urol

Junker K, Zeuschner P (2019). Personalisierte Medizin bei Nierenzelltumoren. Aktuelle Urol. 50(5):513-523

Heinzelmann J, Arndt M, Pleyers R, Fehlmann T, Hoelters S, Zeuschner P, Vogt A, Pryalukhin A, Schaeffeler E, Bohle RM, Gajda M, Janssen M, Stoeckle M, Junker K (2019). 4-miRNA Score Predicts the Individual Metastatic Risk of Renal Cell Carcinoma Patients. Ann Surg Oncol.  26(11): 3765-3773

Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, Osei J, Kaouk J, Redorta JP, Menon M, Peabody J, Dasgupta P, Khan MS, Mottrie A, Stöckle M, Hemal A, Richstone L, Hosseini A, Wiklund P, Schanne F, Kim E, Rha KH, Guru KA (2019). Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol. 202(5):927-935

Rieken M, Herrmann TRW, Füllhase C (2019). Surgical treatment of benign prostatic hyperplasia-resection, vaporization or enucleation. Urologe A. 58(3):263-27

Zeuschner P, Linxweiler J, Junker K (2019). Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn. 18:1-17

Baumgart S, Meschkat P, Edelmann P, Heinzelmann J, Pryalukhin A, Bohle R, Heinzelbecker J, Stöckle M, Junker K (2019). MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle‑invasive bladder cancer. J Cancer Res Clin Oncol. 145(11): 2725–2736

Friedersdorff F, Putz J, Dreikorn K, Giessing M, Fornara P, Stöckle M, Schlomm T (2019). The 2018 annual report on the 26th annual meeting of the working group for kidney transplantation of the German Society of Urology in Berlin. Urologe A. 58(3):324-328

Saar M, Abdeen MSKM, Niklas C, Al-Kailani ZTF, Siemer S, Stöckle M (2019). Trivialization of prostate cancer?: Stage shift and possible causes. Urologe A. 58(12):1461-1468

Zwick A, Bernhard M, Knoerck A, Linxweiler M, Schick B, Heinzelmann J, Smola S, Lohse S (2019). Monitoring kinetics reveals critical parameters of IgA-dependent granulocyte-mediated anti-tumor cell cytotoxicity. J Immunol Methods. 473:112644.

Gong X, Zhao H, Saar M, Peehl DM, Brooks JD (2019). miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. 7;3(2):119-132